Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports
Open Access
- 26 September 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 42 (12), 1487-1498
- https://doi.org/10.1007/s40264-019-00861-y
Abstract
Introduction Adverse event reporting patterns vary between countries, reflecting differences in reporting culture, clinical practice and underlying patient populations. Japan collects about 60,000 domestic adverse event reports yearly and shares serious reports with the World Health Organization (WHO) Programme for International Drug Monitoring in VigiBase, the WHO global database of individual case safety reports. Understanding these reports in the global context can be helpful for regulators worldwide and can aid hypothesis-generation for Japanese-specific vulnerabilities to adverse drug reactions. Objective The objective of this study was to explore differences in the reporting of adverse events between Japan and other countries. Methods vigiPoint is a method for data-driven exploration in pharmacovigilance. It outlines data subsets, pinpoints key features and facilitates expert review, using odds ratios subjected to statistical shrinkage to distinguish one data subset from another. Here, we compared 260,000 Japanese reports in E2B format classified as serious and received in VigiBase between 2013 and 2018 with 2.5 million reports from the rest of the world (of which 51% are from the USA). Reporting patterns for which the 99% credibility interval of the shrunk log-odds ratios were above 0.5 or below − 0.5 were flagged as key features. The shrinkage was set to the vigiPoint default corresponding to 1% of the size of the Japanese data subset. As a sensitivity analysis, additional vigiPoint comparisons were performed between Japan and, in turn, Africa, the Americas, the Americas except the USA and Canada, Asia and Europe. Results There were higher reporting rates in Japan from physicians (83% vs. 39%) and pharmacists (17% vs. 10%). It was also more common to see reports with more than five drugs per report (22% vs. 14%) and with a single adverse event (72% vs. 45%). More than half of the Japanese reports had a vigiGrade completeness score above 0.8 compared with about one in five from the rest of the world. There were more reports than expected for patients aged 70–89 years and fewer reports for adults aged 20–59 years. Adverse events reported more often in Japan included interstitial lung disease, abnormal hepatic function, decreased platelet count, decreased neutrophil count and drug eruption. Adverse events reported less often included death, fatigue, dyspnoea, pain and headache. Drugs reported more often in Japan included prednisolone, methotrexate and peginterferon alfa-2b. Drugs reported less often included rosiglitazone and adalimumab as well as blood substitutes and perfusion solutions. The findings were generally robust to the sensitivity analysis except for the less often reported drugs, many of which were rarely reported in most countries, except in the USA. Conclusion Analysis of Japanese adverse event reporting patterns in a global context has revealed key features that may reflect possible pharmaco-ethnic vulnerabilities in the Japanese, as well as differences in adverse event reporting and clinical practice. This knowledge is essential in the global collaboration of signal detection afforded by the WHO Programme for International Drug Monitoring.This publication has 9 references indexed in Scilit:
- Computed tomography (CT) examsPublished by Organisation for Economic Co-Operation and Development (OECD) ,2017
- A method for data-driven exploration to pinpoint key features in medical data and facilitate expert reviewPharmacoepidemiology and Drug Safety, 2017
- Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®Drug Safety, 2016
- Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilancePharmacoepidemiology and Drug Safety, 2016
- The burden of cardiovascular disease and diabetesWaiting Time Policies in the Health Sector, 2015
- vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality IssuesDrug Safety, 2013
- Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discoveryStatistical Methods in Medical Research, 2011
- Duplicate detection in adverse drug reaction surveillanceData Mining and Knowledge Discovery, 2007
- National differences in reporting ‘pneumonia’ and ‘pneumonia interstitial’: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditionsPharmacoepidemiology and Drug Safety, 2005